FINWIRES · TerminalLIVE
FINWIRES

Verisk Analytics Q1 Adjusted Earnings, Revenue Rise; 2026 Outlook Affirmed

By

-- Verisk Analytics (VRSK) reported Q1 adjusted earnings Wednesday of $1.82 per diluted share, up from $1.73 a year earlier.

Analysts surveyed by FactSet expected $1.74.

Revenue for the quarter ended March 31 was $782.6 million, compared with $753 million a year earlier.

Analysts surveyed by FactSet expected $771.6 million.

For 2026, the company reaffirmed its adjusted EPS guidance of $7.45 to $7.75. Analysts surveyed by FactSet expect $7.62.

Revenue for the year is still projected to be $3.19 billion to $3.24 billion. Analysts surveyed by FactSet expect $3.21 billion.

Shares of the company rose more than 3% pre-bell Wednesday.

Price: $182.00, Change: $+5.34, Percent Change: +3.02%

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS